Both Amgen and Merck write quarterly checks and raise them every year, but only one has the portfolio depth to keep growing ...

Amgen (NASDAQ:AMGN) outlined its growth priorities, late-stage pipeline progress and capital-allocation framework during a ...

Amgen (AMGN) closed the most recent trading day at $385.65, moving +1.55% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.17%. Meanwhile, the Dow lost 0.18%, and ...

Amgen (NASDAQ:AMGN) executives highlighted growth across its key commercial products, progress in late-stage development ...

Amgen (AMGN) stock drops after a phase 3 trial failure for a heart drug from Novartis (NVS) and Ionis Pharma (IONS). BMO ...

Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a ...

Shares of Amgen were recently down more than 9%, putting the biotechnology company on pace for its largest decrease since ...

Bristol Myers Squibb and Ono Pharmaceutical have sued Amgen in Delaware federal court, seeking to block Amgen's proposed U.S.

Amgen ( AMGN) dropped just over 10% on Tuesday after a late-stage cardiovascular trial failure at Novartis raised concerns ...